# A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

> **NCT06490757** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 25 (estimated)

## Conditions studied

- Inflammatory Hepatocellular Adenoma

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT06490757
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2028-09-02
- **Final completion:** 2028-09-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490757, "A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06490757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*